X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (921) 921
index medicus (855) 855
flt3 (732) 732
hematology (604) 604
oncology (557) 557
acute myeloid-leukemia (458) 458
acute myeloid leukemia (428) 428
internal tandem duplication (414) 414
mutation (404) 404
animals (382) 382
leukemia (369) 369
fms-like tyrosine kinase 3 - genetics (347) 347
female (326) 326
aml (323) 323
leukemia, myeloid, acute - genetics (305) 305
male (293) 293
mice (288) 288
cancer (278) 278
acute myelogenous leukemia (263) 263
leukemia, myeloid, acute - drug therapy (252) 252
mutations (244) 244
hemic and lymphatic diseases (227) 227
fms-like tyrosine kinase 3 - antagonists & inhibitors (219) 219
middle aged (219) 219
tyrosine (215) 215
adult (206) 206
flt3 ligand (194) 194
tyrosine kinase inhibitor (187) 187
chemotherapy (184) 184
prognosis (183) 183
expression (176) 176
aged (173) 173
cell line, tumor (173) 173
fms-like tyrosine kinase 3 - metabolism (169) 169
article (161) 161
leukemia, myeloid, acute - pathology (152) 152
research (150) 150
protein kinase inhibitors - pharmacology (148) 148
kinases (143) 143
analysis (142) 142
apoptosis (140) 140
signal transduction (132) 132
phosphorylation (127) 127
immunology (126) 126
adolescent (125) 125
antineoplastic agents - pharmacology (123) 123
sorafenib (123) 123
genetic aspects (122) 122
stem cells (121) 121
cell biology (120) 120
embryonic structures (120) 120
antineoplastic agents - therapeutic use (118) 118
hemic and immune systems (118) 118
activation (112) 112
gene expression (108) 108
cells (107) 107
gene (107) 107
leukemia, myeloid, acute - metabolism (107) 107
myeloid leukemia (107) 107
biochemistry & molecular biology (106) 106
fms-like tyrosine kinase 3 (106) 106
health aspects (106) 106
protein kinase inhibitors - therapeutic use (104) 104
hematology, oncology and palliative medicine (102) 102
in-vivo (99) 99
dendritic cells (97) 97
flt3 mutations (97) 97
in-vitro (97) 97
proteins (96) 96
young adult (95) 95
pharmacology & pharmacy (94) 94
prognostic-significance (94) 94
apoptosis - drug effects (93) 93
constitutive activation (91) 91
cell proliferation - drug effects (90) 90
protein-tyrosine kinase (90) 90
treatment outcome (90) 90
flow cytometry (89) 89
transplantation (89) 89
resistance (87) 87
acute lymphoblastic-leukemia (86) 86
child (86) 86
cell proliferation (85) 85
flt3 inhibitors (85) 85
fluids and secretions (85) 85
myelodysplastic syndrome (84) 84
flt3 inhibitor (83) 83
gene mutations (83) 83
inhibitors (83) 83
therapy (82) 82
chemistry, medicinal (81) 81
signal transduction - drug effects (81) 81
tandem repeat sequences (81) 81
kinase inhibitor (80) 80
leukemia, myeloid, acute - mortality (80) 80
receptor (80) 80
survival (79) 79
bone marrow (78) 78
minimal residual disease (78) 78
medicine & public health (76) 76
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
International Journal of Nanomedicine, ISSN 1176-9114, 02/2016, Volume 11, pp. 641 - 660
Background and aims: Every year, in Europe, acute myeloid leukemia (AML) is diagnosed in thousands of adults. For most subtypes of AML, the backbone of... 
Acute myeloid leukemia | Gold nanoparticles | Tyrosine kinase inhibitors | GENE-MUTATIONS | TARGET | gold nanoparticles | FLT3 | NANOSCIENCE & NANOTECHNOLOGY | TANDEM DUPLICATION | SORAFENIB | COMBINATION | CHEMOTHERAPY | tyrosine kinase inhibitors | EVOLUTION | acute myeloid leukemia | PHARMACOLOGY & PHARMACY | CHEMORESISTANCE | PHASE-I | Gold - chemistry | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Gold - administration & dosage | Apoptosis - drug effects | Leukemia, Myeloid, Acute - pathology | Humans | Leukemia, Myeloid, Acute - metabolism | Metal Nanoparticles - chemistry | RNA, Messenger - genetics | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | fms-Like Tyrosine Kinase 3 - metabolism | Drug Carriers | Drug Delivery Systems | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - chemistry | Metal Nanoparticles - administration & dosage | Leukemia, Myeloid, Acute - drug therapy | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Tumor Cells, Cultured | Real-Time Polymerase Chain Reaction | Nanoparticles | Tyrosine | Phenols | Care and treatment | Cancer | Cell culture | Transplants & implants | Hematology | Leukemia | Genomics | Systematic review | Kinases | Medicine | Chemotherapy | Microscopy | Pharmacy | Mutation
Journal Article
Drug Resistance Updates, ISSN 1368-7646, 2008, Volume 12, Issue 1, pp. 8 - 16
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 06/2013, Volume 161, Issue 5, pp. 659 - 666
Journal Article
CHEMICAL BIOLOGY & DRUG DESIGN, ISSN 1747-0277, 05/2018, Volume 91, Issue 5, pp. 1056 - 1064
Fms-like tyrosine kinase 3 (FLT3) belongs to the receptor tyrosine kinase family and expressed in hematopoietic progenitor cells. FLT3 gene mutations are... 
MYCOBACTERIUM-TUBERCULOSIS | CHEMISTRY, MEDICINAL | PROTEIN | FLT3 | MZH29 | BIOCHEMISTRY & MOLECULAR BIOLOGY | molecular dynamics simulation | ACUTE MYELOID-LEUKEMIA | IDENTIFICATION | MOLECULAR-DYNAMICS SIMULATION | quizartinib | F691L mutation | crenolanib | RESISTANCE | EFFICIENT
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 113, Issue 17, pp. 4063 - 4073
Currently, FLT3 tyrosine kinase inhibitors (TKIs) are emerging as the most promising drug therapy to overcome the dismal prognosis of acute myelogenous... 
WILD-TYPE | ACTIVATING MUTATION | GRB2-SH2 DOMAIN | LESTAURTINIB CEP701 | FLT3 INHIBITORS | THERAPEUTIC TARGET | TYROSINE KINASE INHIBITOR | CLINICAL RESISTANCE | ACUTE MYELOID-LEUKEMIA | FLT3-ACTIVATING MUTATIONS | HEMATOLOGY | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Humans | Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors | Substrate Specificity | Staurosporine - analogs & derivatives | Antineoplastic Agents - therapeutic use | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myeloid, Acute - enzymology | Leukemia, Myeloid, Acute - drug therapy | Gene Expression Regulation, Neoplastic - drug effects | Gene Expression Regulation, Neoplastic - genetics | Leukemia, Myeloid, Acute - pathology | Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors | Down-Regulation - drug effects | Enzyme Activation - drug effects | fms-Like Tyrosine Kinase 3 - metabolism | Up-Regulation - drug effects | Phenotype | Animals | Mitogen-Activated Protein Kinase 3 - metabolism | Signal Transduction - drug effects | Staurosporine - therapeutic use | Cell Line, Tumor | Protein Array Analysis | Mice | Staurosporine - pharmacology | Drug Resistance, Neoplasm - drug effects | Leukemia, Myeloid, Acute - genetics | Mitogen-Activated Protein Kinase 1 - metabolism | Clinical Medicine | Hematologi | Medical and Health Sciences | Hematology | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Immunologic Research, ISSN 0257-277X, 10/2014, Volume 60, Issue 1, pp. 112 - 126
Psoriasis is a common chronic T-cell-mediated autoimmune skin disease, and traditional immunotherapies for psoriasis have focused on the direct inhibition of T... 
Allergology | Immunology | Medicine & Public Health | FLT3 + CD11c + DCs | Psoriasis | Immunotherapy | Internal Medicine | Medicine/Public Health, general | FLT3 inhibitor | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | COLONY-STIMULATING FACTOR | PLASMACYTOID PREDENDRITIC CELLS | BONE-MARROW | DELTA T-CELLS | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | FLT3(+) CD11c(+) DCs | IN-VIVO | TYROSINE KINASE INHIBITOR | ANTIGEN-PRESENTING CELLS | SKIN INFLAMMATION | Psoriasis - immunology | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Psoriasis - drug therapy | Anti-Inflammatory Agents - pharmacology | Dermatitis - immunology | Dendritic Cells - immunology | Humans | Phenylurea Compounds - therapeutic use | Mice, Transgenic | fms-Like Tyrosine Kinase 3 - immunology | Vascular Endothelial Growth Factor A - genetics | CD11c Antigen - immunology | Keratin-14 - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Thiadiazoles - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Mice, Inbred BALB C | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Disease Models, Animal | Thiadiazoles - pharmacology | Endothelial growth factors | Dendritic cells | Dermatology | Analysis | Formulae, receipts, prescriptions | Animal genetic engineering | Dermatologic agents | Skin | T cells | Index Medicus
Journal Article